{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:21:25Z","timestamp":1762867285500,"version":"3.37.3"},"reference-count":68,"publisher":"BMJ","issue":"5","funder":[{"DOI":"10.13039\/501100008164","name":"Muscular Dystrophy UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008164","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000589","name":"Chief Scientist Office","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000589","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:p>Evaluation of bone health in childhood is important to identify children who have inadequate bone mineralisation and who may benefit from interventions to decrease their risk of osteoporosis and subsequent fracture. There are no bone protective agents that are licensed specifically for the prevention and treatment of osteoporosis in children. In this review, we discuss the mechanism of action and use of bisphosphonates and other new and established bone protective agents in children.<\/jats:p>","DOI":"10.1136\/archdischild-2016-311820","type":"journal-article","created":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T16:15:13Z","timestamp":1508861713000},"page":"503-508","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Bone protective agents in children"],"prefix":"10.1136","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-5174","authenticated-orcid":false,"given":"Claire Louise","family":"Wood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S Faisal","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,10,24]]},"reference":[{"key":"2020050712442190000_103.5.503.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-2760(00)00336-2"},{"key":"2020050712442190000_103.5.503.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.6.785"},{"key":"2020050712442190000_103.5.503.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2014.01.003"},{"key":"2020050712442190000_103.5.503.4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000447583","article-title":"Skeletal Fragility in Children with Chronic Disease","volume":"86","author":"Joseph","year":"2016","journal-title":"Horm Res Paediatr"},{"key":"2020050712442190000_103.5.503.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810013391402"},{"key":"2020050712442190000_103.5.503.6","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199707000-00005"},{"key":"2020050712442190000_103.5.503.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-007-0540-8"},{"key":"2020050712442190000_103.5.503.8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2413"},{"key":"2020050712442190000_103.5.503.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc076064"},{"key":"2020050712442190000_103.5.503.10","first-page":"654","article-title":"Reproduction toxicity studies with pamidronate","volume":"42","author":"Graepel","year":"1992","journal-title":"Arzneimittelforschung"},{"key":"2020050712442190000_103.5.503.11","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp140041"},{"key":"2020050712442190000_103.5.503.12","doi-asserted-by":"publisher","DOI":"10.1007\/BF00350961"},{"key":"2020050712442190000_103.5.503.13","first-page":"Cd005088","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"7","author":"Dwan","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2020050712442190000_103.5.503.14","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1515\/jpem-2006-190410","article-title":"Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis","volume":"19","author":"Unal","year":"2006","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2020050712442190000_103.5.503.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61091-0"},{"key":"2020050712442190000_103.5.503.16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0636"},{"key":"2020050712442190000_103.5.503.17","doi-asserted-by":"crossref","unstructured":"Ward L , Tricco AC , Phuong P , et al . Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev 2007:CD005324.doi:10.1002\/14651858.CD005324.pub2","DOI":"10.1002\/14651858.CD005324.pub2"},{"key":"2020050712442190000_103.5.503.18","doi-asserted-by":"publisher","DOI":"10.1136\/adc.86.5.356"},{"key":"2020050712442190000_103.5.503.19","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2002.128207"},{"key":"2020050712442190000_103.5.503.20","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1515\/jpem-2014-0527","article-title":"Effects of bisphosphonates to treat osteoporosis in children with cerebral palsy: a meta-analysis","volume":"28","author":"Kim","year":"2015","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2020050712442190000_103.5.503.21","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1469-8749.2009.03384.x","article-title":"Epidemiology of low bone mineral density and fractures in children with severe cerebral palsy: a systematic review","volume":"51","author":"Mergler","year":"2009","journal-title":"Dev Med Child Neurol"},{"key":"2020050712442190000_103.5.503.22","doi-asserted-by":"publisher","DOI":"10.1177\/0883073810371004"},{"key":"2020050712442190000_103.5.503.23","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2015-308654"},{"key":"2020050712442190000_103.5.503.24","doi-asserted-by":"publisher","DOI":"10.1177\/000992280304200408"},{"key":"2020050712442190000_103.5.503.25","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-1666"},{"key":"2020050712442190000_103.5.503.26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/mus.24991","article-title":"Prophylactic oral bisphosphonate therapy in duchenne muscular dystrophy","volume":"54","author":"Srinivasan","year":"2016","journal-title":"Muscle Nerve"},{"key":"2020050712442190000_103.5.503.27","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/jbmr.2756","article-title":"Histomorphometry and bone matrix mineralization before and after bisphosphonate treatment in boys with duchenne muscular dystrophy: a paired transiliac biopsy study","volume":"31","author":"Misof","year":"2016","journal-title":"J Bone Miner Res"},{"key":"2020050712442190000_103.5.503.28","first-page":"CD010899","article-title":"Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy","volume":"1","author":"Bell","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2020050712442190000_103.5.503.29","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/21678707.2016.1148596","article-title":"Bisphosphonate use in Duchenne Muscular Dystrophy \u2013 why","volume":"4","author":"Wood","year":"2016","journal-title":"when to start and when to stop? Expert Opin Orphan Drugs"},{"key":"2020050712442190000_103.5.503.30","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1754.2003.00083.x"},{"key":"2020050712442190000_103.5.503.31","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1210\/jc.2015-2680","article-title":"Short-term safety of zoledronic acid in young patients with bone disorders: an extensive institutional experience","volume":"100","author":"George","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2020050712442190000_103.5.503.32","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040814"},{"key":"2020050712442190000_103.5.503.33","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.0707onj"},{"key":"2020050712442190000_103.5.503.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2008.12.005"},{"key":"2020050712442190000_103.5.503.35","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.5037\/jomr.2013.4401","article-title":"Systematic review on the incidence of bisphosphonate related osteonecrosis of the jaw in children diagnosed with osteogenesis imperfecta","volume":"4","author":"Hennedige","year":"2013","journal-title":"J Oral Maxillofac Res"},{"key":"2020050712442190000_103.5.503.36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.bdj.2009.5","article-title":"Dental extractions and bisphosphonates: the assessment, consent and management, a proposed algorithm","volume":"206","author":"Malden","year":"2009","journal-title":"Br Dent J"},{"key":"2020050712442190000_103.5.503.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0910389"},{"key":"2020050712442190000_103.5.503.38","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2016.07.022","article-title":"Atypical femur fracture in an adolescent boy treated with bisphosphonates for X-linked osteoporosis based on PLS3 mutation","volume":"91","author":"van de Laarschot","year":"2016","journal-title":"Bone"},{"key":"2020050712442190000_103.5.503.39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1403799"},{"key":"2020050712442190000_103.5.503.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa023110"},{"key":"2020050712442190000_103.5.503.41","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jsams.2014.07.022","article-title":"Effects of vitamin D supplementation on upper and lower body muscle strength levels in healthy individuals. A systematic review with meta-analysis","volume":"18","author":"Tomlinson","year":"2015","journal-title":"J Sci Med Sport"},{"key":"2020050712442190000_103.5.503.42","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b5664"},{"key":"2020050712442190000_103.5.503.43","unstructured":"SACN. Vitamin D and Health report. 2016."},{"key":"2020050712442190000_103.5.503.44","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2015-308299"},{"key":"2020050712442190000_103.5.503.45","doi-asserted-by":"publisher","DOI":"10.1677\/JOE-10-0045"},{"key":"2020050712442190000_103.5.503.46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03686.x"},{"key":"2020050712442190000_103.5.503.47","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2600"},{"key":"2020050712442190000_103.5.503.48","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.070715"},{"issue":"Suppl 1","key":"2020050712442190000_103.5.503.49","first-page":"1","article-title":"Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle","volume":"56 Suppl 1","author":"Stewart","year":"2001","journal-title":"Horm Res"},{"key":"2020050712442190000_103.5.503.50","doi-asserted-by":"publisher","DOI":"10.1210\/er.2004-0006"},{"key":"2020050712442190000_103.5.503.51","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/jbmr.2454","article-title":"Mapping bone changes at the proximal femoral cortex of postmenopausal women in response to alendronate and teriparatide alone, combined or sequentially","volume":"30","author":"Whitmarsh","year":"2015","journal-title":"J Bone Miner Res"},{"key":"2020050712442190000_103.5.503.52","doi-asserted-by":"publisher","DOI":"10.1080\/01926230252929882"},{"key":"2020050712442190000_103.5.503.53","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-009-1004-0"},{"key":"2020050712442190000_103.5.503.54","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1908"},{"key":"2020050712442190000_103.5.503.55","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.12.4358"},{"key":"2020050712442190000_103.5.503.56","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1542\/peds.62.6.1189","article-title":"Treatment of tall girls with estrogen","volume":"62","author":"Crawford","year":"1978","journal-title":"Pediatrics"},{"key":"2020050712442190000_103.5.503.57","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/SHK.0000000000000517","article-title":"Five-year outcomes after long-term oxandrolone adminstration in severely burned children: a randomized clinical trial","volume":"45","author":"Reeves","year":"2016","journal-title":"Shock"},{"key":"2020050712442190000_103.5.503.58","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.447"},{"key":"2020050712442190000_103.5.503.59","doi-asserted-by":"publisher","DOI":"10.1249\/mss.0b013e318149f111"},{"key":"2020050712442190000_103.5.503.60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809493"},{"key":"2020050712442190000_103.5.503.61","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13023-014-0145-1","article-title":"Two years' experience with denosumab for children with osteogenesis imperfecta type VI","volume":"9","author":"Hoyer-Kuhn","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"2020050712442190000_103.5.503.62","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00774-015-0677-z","article-title":"Severe hypercalcemia following denosumab treatment in a juvenile patient","volume":"34","author":"Setsu","year":"2016","journal-title":"J Bone Miner Metab"},{"key":"2020050712442190000_103.5.503.63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/6217286","article-title":"Sclerostin antibody therapy for the treatment of osteoporosis: clinical prospects and challenges","volume":"2016","author":"MacNabb","year":"2016","journal-title":"J Osteoporos"},{"key":"2020050712442190000_103.5.503.64","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1717"},{"key":"2020050712442190000_103.5.503.65","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2351"},{"key":"2020050712442190000_103.5.503.66","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00198-015-3308-6","article-title":"Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength","volume":"27","author":"Yao","year":"2016","journal-title":"Osteoporos Int"},{"key":"2020050712442190000_103.5.503.67","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00223-015-0051-0","article-title":"Cathepsin K inhibition: a new mechanism for the treatment of osteoporosis","volume":"98","author":"Duong","year":"2016","journal-title":"Calcif Tissue Int"},{"key":"2020050712442190000_103.5.503.68","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-014-2944-6"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2016-311820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:22:15Z","timestamp":1719534135000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2016-311820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,24]]},"references-count":68,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,4,19]]},"published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1136\/archdischild-2016-311820"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2016-311820","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"type":"print","value":"0003-9888"},{"type":"electronic","value":"1468-2044"}],"subject":[],"published":{"date-parts":[[2017,10,24]]}}}